drugset / Trial / NCT06488378
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)
Timeline
- Start
- 2024-08-13
- Primary completion
- 2026-09-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axatilimab | Monoclonal antibody | — | Intravenous |
| Background | Olaparib | Small molecule | 100 mg | Oral |
| Background | Olaparib | Small molecule | 150 mg | Oral |